What is Juvenescence?
Juvenescence Limited operates at the intersection of biotechnology and preventative medicine, focusing on the development of therapies designed to slow, halt, or reverse the biological markers of aging. Founded by industry veterans Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, the company employs a unique business model that involves in-licensing promising compounds from academic institutions and forming strategic joint ventures. By leveraging a deep understanding of the biology of aging, Juvenescence aims to address the root causes of age-related decline, positioning itself as a leader in the burgeoning longevity therapeutics market.
How much funding has Juvenescence raised?
Juvenescence has raised a total of $256.9M across 4 funding rounds:
Angel/Seed
$50M
Series A
$50M
Series B
$100M
Series C
$56.9M
Angel/Seed (2018): $50M, investors not publicly disclosed
Series A (2018): $50M, investors not publicly disclosed
Series B (2019): $100M supported by Grok Ventures and IPGL
Series C (2020): $56.9M, investors not publicly disclosed
Key Investors in Juvenescence
Grok Ventures
Grok Ventures is a venture capital and private equity firm that provides strategic backing to high-growth companies, leveraging its expertise to support long-term enterprise development.
IPGL
IPGL is a private holding company that partners with experienced management teams to build industry leaders, utilizing proprietary expertise to accelerate growth across diverse sectors including healthcare.
Undisclosed Investor
An undisclosed institutional investor participating in the funding round to support the advancement of longevity-focused therapeutic research.
What's next for Juvenescence?
With the recent capital injection, Juvenescence is well-positioned to accelerate its pipeline of longevity-related therapeutics. The company's strategic roadmap likely involves expanding its portfolio of in-licensed assets and deepening its clinical trial capabilities. As the firm moves into its next phase of development, it will likely focus on optimizing its joint venture partnerships to bring innovative treatments to market. The emphasis remains on rigorous scientific validation and the commercialization of therapies that could fundamentally alter the human health span, providing a robust foundation for long-term value creation in the life sciences industry.
See full Juvenescence company page
